Evidence map›Paper›PMID 36560812›Full record

SynthesisViruses2022

Human T-Cell Leukemia Virus Type 1-Related Diseases May Constitute a Threat to the Elimination of Human Immunodeficiency Virus, by 2030, in Gabon, Central Africa.

Eldridge Fedricksen Oloumbou, Jéordy Dimitri Engone-Ondo, Issakou Mamimandjiami Idam, Pamela Moussavou-Boudzanga, Ivan Mfouo-Tynga, Augustin Mouinga-Ondeme

Open access · goldAbstract readSystematic Review
In one paragraph

Synthesis in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Eldridge Fedricksen OloumbouUnité des Infection Rétrovirales et Pathologies Associées, Centre International de Recherches Médicales de Franceville (CIRMF), Franceville BP 769, Gabon.ORCID 0000-0002-0895-2909
Jéordy Dimitri Engone-OndoUnité des Infection Rétrovirales et Pathologies Associées, Centre International de Recherches Médicales de Franceville (CIRMF), Franceville BP 769, Gabon.
Issakou Mamimandjiami IdamUnité des Infection Rétrovirales et Pathologies Associées, Centre International de Recherches Médicales de Franceville (CIRMF), Franceville BP 769, Gabon.
Pamela Moussavou-BoudzangaUnité des Infection Rétrovirales et Pathologies Associées, Centre International de Recherches Médicales de Franceville (CIRMF), Franceville BP 769, Gabon.
Ivan Mfouo-TyngaUnité des Infection Rétrovirales et Pathologies Associées, Centre International de Recherches Médicales de Franceville (CIRMF), Franceville BP 769, Gabon.
Augustin Mouinga-OndemeUnité des Infection Rétrovirales et Pathologies Associées, Centre International de Recherches Médicales de Franceville (CIRMF), Franceville BP 769, Gabon.ORCID 0000-0002-3143-1060
Centre International de Recherches Médicales de Franceville · GA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Joint United Nations Program on HIV/AIDS (UNAIDS) has adopted the Sustainable Development Goals (SDGs) to end the HIV/AIDS epidemic by 2030. Several factors related to the non-suppression of HIV, including interruptions of antiretroviral therapy (ART) and opportunistic infections could affect and delay this projected epidemic goal. Human T-Cell leukemia virus type 1 (HTLV-1) appears to be consistently associated with a high risk of opportunistic infections, an early onset of HTLV-1 and its associated pathologies, as well as a fast progression to the AIDS phase in co-infected individuals, when compared to HIV-1 or HTLV-1 mono-infected individuals. In Gabon, the prevalence of these two retroviruses is very high and little is known about HTLV-1 and the associated pathologies, leaving most of them underdiagnosed. Hence, HTLV-1/HIV-1 co-infections could simultaneously imply a non-diagnosis of HIV-1 positive individuals having developed pathologies associated with HTLV-1, but also a high mortality rate among the co-infected individuals. All of these constitute potential obstacles to pursue targeted objectives. A systematic review was conducted to assess the negative impacts of HTLV-1/HIV-1 co-infections and related factors on the elimination of HIV/AIDS by 2030 in Gabon.

Indexed as

Acquired Immunodeficiency SyndromeCoinfectionHIV-1HIV InfectionsHIV SeropositivityHTLV-I InfectionsHuman T-lymphotropic virus 1Leukemia, T-CellOpportunistic InfectionsGabonHumanscoinfectionGabongenetic diversityHIV-1HIV eliminationHTLV-1HTLV-1-associated pathologies

Identifiers

PMID36560812
PMCPMC9785256
OpenAlexW4312211472

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.